PLUS THERAPEUTICS INC
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
2(a): Unregistered Sales of Equity Securities and Use of Proceeds
None.
2(b): Use of Proceeds from Registered Securities
None.
2(c): Purchases of Equity Securities
The following table provides certain information with respect to the Company’s purchases of the Company’s common stock for the three months ended March 31, 2024:
| Company Purchases of Common stock | |||
|---|---|---|---|
| Period | Total number of shares purchased | Average price paid per share | Approximate dollar value of shares that may yet be purchased under plan or programs (1) |
| January 1, 2024 through January 31, 2024 | 102,194 | $2.02 | $157,000 |
| February 1, 2024 through February 29, 2024 | 77,062 | $1.96 | $1,000 |
| March 1, 2024 through March 31, 2024 | 610 | $2.01 | $0 |
| Total | 179,866 | $1.99 | $0 |
(1) On October 31, 2023, the Company announced that the Board authorized a $500,000 a share repurchase program (the “Share Repurchase Program”). Repurchases are funded from available cash and may be made at management’s discretion from time to time. As of March 31, 2024, there was no remaining amount available for future share repurchases under the Share Repurchase Program. The repurchase authorization will expire on October 31, 2024. Refer to Note 10. Stockholders’ Equity in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information on the Share Repurchase Program.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.